CD86 and cancer: Vaccines adjuvanted with STING agonists mediate robust immune defense against infections and cancer by promoting the maturation of antigen‐presenting cells (APCs) and activation of T cells.[35] Our data further confirmed these conclusions; the co‐stimulatory molecules CD40 and CD86 and the levels of IL‐12p70 and IL‐6 induced by rSC0120 in BMDCs and BMDMs were significantly higher than those induced by rSC0119 (Figure 4I–K; Figure S5, Supporting Information).